RISK OF FEBRILE NEUTROPENIA AND USE OF G-CSF PRIMARY PROPHYLAXIS IN NON-HODGKIN'S LYMPHOMA PATIENTS RECEIVING R-CHOP-21

被引：0

作者：

Haioun, C. ^{[1
]}

Jaeger, U. ^{[2
]}

Lugtenburg, P. ^{[3
]}

Pettengell, R. ^{[4
]}

Principe, F. ^{[5
]}

Rossi, F. ^{[6
]}

Salar, A. ^{[7
]}

Schwenkglenks, M. ^{[8
]}

Verhoef, G. ^{[9
]}

Edmundson, S. ^{[10
]}

Bacon, P. ^{[11
]}

机构：

[1] CHU Henri Mondor, F-94010 Creteil, France

[2] Univ Klinikum, Vienna, Austria

[3] Erasmus MC, Rotterdam, Netherlands

[4] St Georges Univ London, London, England

[5] Hosp San Joao, Oporto, Portugal

[6] Univ Milan, CTMO Fdn, OM PoMaRe IRCCS, Milan, Italy

[7] Hosp Mar IMAS, Barcelona, Spain

[8] Univ Basel Hosp, European Ctr Pharmaceut Med, CH-4031 Basel, Switzerland

[9] Univ Hosp Gasthuisberg, B-3000 Louvain, Belgium

[10] Amgen Ltd, Uxbridge, Middx, England

[11] ZUC, Amgen Europe GmbH, Zurich, Switzerland

来源：

HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2008年 / 93卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

0258

引用

页码：105 / 105

页数：1

共 50 条

[1] PREDICTORS OF G-CSF PROPHYLAXIS IN THE FIRST CYCLE OF CHEMOTHERAPY FOR FEBRILE NEUTROPENIA IN PATIENTS WITH NON-HODGKIN'S LYMPHOMA
Lugtenburg, P.
Asubonteng, J.
DeCosta, L.
Szabo, Z.
Page, J. H.
Wetten, S.
[J]. HAEMATOLOGICA, 2014, 99 : 196 - 196
[2] Primary prophylaxis against febrile neutropenia with pegfilgrastim is cost-effective compared with filgrastim in non-Hodgkin's lymphoma patients receiving CHOP-21 in Spain
Lopez, A.
Arocho, R.
Atchison, C.
Malin, J. L.
Liu, Z.
Doan, Q., V
Dubois, R. W.
[J]. VALUE IN HEALTH, 2007, 10 (06) : A324 - A324
[3] Primary prophylaxis against febrile neutropenia with pegfilgrastim is cost-effective compared with filgrastim in non-Hodgkin's lymphoma patients receiving CHOP-21 in Italy
Chiroli, S.
Ciceri, D. F.
Atchison, C.
Malin, J. L.
Liu, Z.
Doan, Q., V
Dubois, R. W.
[J]. VALUE IN HEALTH, 2007, 10 (06) : A329 - A329
[4] Risk of febrile neutropenia among patients with intermediate-grade non-Hodgkin's lymphoma receiving CHOP chemotherapy
Lyman, GH
Morrison, VA
Dale, DC
Crawford, J
Delgado, DJ
Fridman, M
[J]. LEUKEMIA & LYMPHOMA, 2003, 44 (12) : 2069 - 2076
[5] G-CSF primary prophylaxis use and outcomes in patients receiving chemotherapy at intermediate risk for febrile neutropenia: a scoping review
Campbell, Kim
Chadha, Nidhi
Dimri, Seema
Wang, Weijia
Li, Edward
[J]. EXPERT REVIEW OF HEMATOLOGY, 2022, 15 (07) : 619 - 633
[6] Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOP-R, or CNOP chemotherapy for intermediate-grade non-Hodgkin lymphoma
Lyman, GH
Delgado, DJ
[J]. CANCER, 2003, 98 (11) : 2402 - 2409
[7] Evaluation of the impact of timing of pegfilgrastim administration on incidence of febrile neutropenia in elderly patients with B-cell non-Hodgkin lymphomas receiving R-CHOP-21
Lei, Matthew M.
Watson, Aleksandra N.
Abramson, Jeremy S.
[J]. LEUKEMIA & LYMPHOMA, 2020, 61 (12) : 2998 - 3001
[8] Incidence and risk factors for febrile neutropenia of patients with diffuse large B-cell lymphoma receiving R-CHOP-21 in China
Zheng, Wenshuai
Chen, Zhaoguang
Zhu, Shibin
Cheng, Longcan
Hu, Yalei
Yang, Yuhui
Tan, Min
Ning, Hongmei
Guan, Lixun
[J]. SUPPORTIVE CARE IN CANCER, 2024, 32 (01)
[9] Incidence and risk factors for febrile neutropenia of patients with diffuse large B-cell lymphoma receiving R-CHOP-21 in China
Wenshuai Zheng
Zhaoguang Chen
Shibin Zhu
Longcan Cheng
Yalei Hu
Yuhui Yang
Min Tan
Hongmei Ning
Lixun Guan
[J]. Supportive Care in Cancer, 2024, 32
[10] A probability/risk matrix of febrile neutropenia to select patients for G-CSF primary prophylaxis
Ramchandani Vaswani, A.
Faez, L.
Selvi Miralles, M.
Antonio-Rebollo, M.
Font Puig, C.
Espinosa Arranz, J.
Biosca, M.
Vicente Rubio, E.
Jimenez Fonseca, P.
Carmona-Bayonas, A.
[J]. EUROPEAN JOURNAL OF CANCER, 2013, 49 : S275 - S276

← 1 2 3 4 5 →